Is Nottingham prognostic index useful after induction chemotherapy in operable breast cancer?

P Chollet, S Amat, E Belembaogo, H Curé, M de Latour, J Dauplat, G Le Bouëdec, M-A Mouret-Reynier, J-P Ferrière, F Penault-Llorca, P Chollet, S Amat, E Belembaogo, H Curé, M de Latour, J Dauplat, G Le Bouëdec, M-A Mouret-Reynier, J-P Ferrière, F Penault-Llorca

Abstract

The Nottingham prognostic index (NPI), based on tumour size in breast, node involvement and Scarff-Bloom-Richardson (SBR) grading, has been shown to constitute a definitive prognostic factor of primary operable breast cancer in the adjuvant setting. We performed a retrospective study to evaluate the prognostic value of this index in 163 patients after neoadjuvant chemotherapy. Secondly, we examined the influence on survival of a revised NPI, only based on residual tumour size in breast and SBR grading in 228 patients, and consequently called breast grading index (BGI). The prognostic value of these two indices was also evaluated by replacing the SBR grade with the MSBR grade, a French modified SBR grading; the modified NPI (MNPI) and modified BGI (MBGI) were, respectively, obtained in 153 and 222 patients. At a median follow-up of 9.3 years, survival was significantly related to these four indices (P<0.001). Multivariate analysis revealed that MBGI was the only one which retained a prognostic influence on disease-free survival (P<0.02). In conclusion, the 'amount' of residual tumour in breast and/or nodes, as defined by NPI and revised indices, confers a determinant prognosis after neoadjuvant chemotherapy, inviting an alternative postsurgical treatment for a subgroup of patients with a decreased survival.

Figures

Figure 1
Figure 1
Univariate analysis of OS and DFS as a function of NPI based on SBR grading after neoadjuvant chemotherapy, with or without lymph-node stage.
Figure 2
Figure 2
Univariate analysis of OS and DFS as a function of NPI based on MSBR grading after neoadjuvant chemotherapy, with or without lymph-node stage.

References

    1. Adjuvant Therapy for Breast Cancer (2000) NIH consensus statement. 17(4): 1–35
    1. Amat S, Penault-Llorca F, Cure H, Le Bouedec G, Achard JL, Van Praagh I, Feillel V, Mouret-Reynier MA, Dauplat J, Chollet P (2002) Scarff–Bloom–Richardson (SBR) grading: a pleiotropic marker of chemosensitivity in invasive ductal breast carcinomas treated by neoadjuvant chemotherapy. Int J Oncol 20: 791–796
    1. Balslev I, Axelsson CK, Zedeler K, Rasmussen BB, Carstensen B, Mouridsen HT (1994) The Nottingham prognostic index applied to 9,149 patients from the studies of the Danish breast Cancer Cooperative Group (DBCG). Breast Cancer Res Treat 32: 281–290
    1. Belembaogo E, Feillel V, Chollet P, Cure H, Verrelle P, Kwiatkowski F, Achard JL, Le Bouëdec G, Chassagne J, Bignon Y-J, de Latour M, Lafaye C, Dauplat J (1992) Neoadjuvant chemotherapy in 126 operable breast cancers. Eur J Cancer 28A(4/5): 896–900
    1. Cameron DA, Anderson ED, Levack P, Hawkins RA, Anderson TJ, Leonard RC, Forrest AP, Chetty U (1997) Primary systemic therapy for operable breast cancer – 10-year survival data after chemotherapy and hormone therapy. Br J Cancer 76: 1099–1105
    1. Charpin C, Bacquie N, Bouvier C, Devictor B, Boulat J, Andrac L, Lavaut MN, Allasia C, Piana L (1995) Comparison of the prognostic significance of current and modified histological grades in breast carcinomas. Anticancer Res 15(6B): 2611–2617
    1. Chollet P, Amat S, Cure H, de Latour M, Le Bouedec G, Mouret-Reynier MA, Ferriere JP, Achard JL, Dauplat J, Penault-Llorca F (2002) Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer. Br J Cancer 86(7): 1041–1046
    1. Chollet P, Amat S, Penault-Llorca F, Fetissol F, Body G, Mouret-Reynier MA, Bons JM, Cure H, Dauplat J, Baugnoux P, (2000) High pathological response rate induced by primary docetaxel monotherapy in operable breast cancer. Breast Cancer Res Treat 64: 67 [abstract no. 251]
    1. Chollet P, Charrier S, Brain E, Cure H, Van Praagh I, Feillel V, de Latour M, Dauplat J, Misset JL, Ferriere JP (1997) Clinical and pathological response to primary chemotherapy in operable breast cancer. Eur J Cancer 33: 862–866
    1. Cox DR (1972) Regression models and life tables. JR Stat Soc B 34: 187–202
    1. Cure H, Amat S, Peault-Llorca F, Le Bouëdec G, Ferriere JP, Mouret-Reynier MA, Kwiatkowski F, Feillel V, Dauplat J, Chollet P (2002) Prognostic value of residual node involvement in operable breast cancer after chemotherpy. Breast Cancer Res Treat 76(1): 37–45
    1. D'Eredita G, Giardina C, Martellotta M, Natale T, Ferrarese F (2001) Prognostic factors in breast cancer: the predictive value of the Nottingham Prognostic Index in patients with a long-term follow-up that were treated in a single institution. Eur J Cancer 37(5): 591–596
    1. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A, Margolese RG, Cruz Jr AB, Hoehn JL, Lees AW, Dimitrov NV, Bear HD (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16: 2672–2685
    1. Fredriksson I, Liljegren G, Arnesson L, Emdin S, Palm-Sjovall M, Fornander T, Holmqvist M, Holmberg L, Frisell J (2002) Local recurrence in the breast after conservative surgery – a study of prognosis and prognostic factors in 391 women. Eur J Cancer 38(14): 1860–1870
    1. Galea MH, Blamey RW, Elston CE, Ellis IO (1992) The Nottingham prognostic index in primary breast cancer. Breast Cancer Res Treat 22: 207–219
    1. Haybittle JL, Blamey RW, Elston CW, Johnson J, Doyle PJ, Campbell FC, Nicholson RI, Griffiths K (1982) A prognostic index in primary breast cancer. Br J Cancer 45: 361–366
    1. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. Clinical course of breast cancer. J Am Stat assoc 185: 1457–1481
    1. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, Theriault RL, Singh G, Binkley SM, Sneige N, Buchholz TA, Ross MI, McNeese MD, Buzdar AU, Hortobagyi GN, Singletary SE (1999) Clinical course of breast cancer patients with complete pathologic primary tumour and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17(2): 460–469
    1. Latinovic L, Heinze G, Birner P, Samonigg H, Hausmaninger H, Kubista E, Kwasny W, Gnant M, Jakesz R, Oberhuber G, The Austrian Breast and Colorectal Cancer Study Group (2001) Prognostic relevance of three histological grading methods in breast cancer. Int J Oncol 19(6): 1271–1277
    1. Le Doussal V, Tubiana-Hulin M, Friedman S, Hacene K, Spyratos F, Brunet M (1989) Prognostic value of histologic grade nuclear components of Scarff–Bloom–Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer 64(9): 1914–1921
    1. Machiavelli MR, Romero AO, Perez JE, Lacava JA, Dominguez ME, Rodriguez ME, Barbieri MR, Romero Acuna LA, Romero Acuna JM, Langhi MJ, Amato S, Ortiz EH, Vallejo CT, Leone BA (1998) Prognostic significance of pathological response of primary tumour and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma. Cancer J Sci Am 4(2): 125–131
    1. Makris A, Powles TJ, Allred DC, Ashley SE, Trott PA, Ormerod MG, Titley JC, Dowsett M (1999) Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: a pilot study. Breast Cancer Res Treat 53(1): 51–59
    1. Malmstrom P, Bendahl PO, Boiesen P, Brunner N, Idvall I, Ferno M, South Sweden Breast Cancer Group (2001) S-phase fraction and urokinase plasminogen activator are better markers for distant recurrences than Nottingham Prognostic Index and histologic grade in a prospective study of premenopausal lymph node-negative breast cancer. J Clin Oncol 19(7): 2010–2019
    1. Mantel N (1966) Evaluation of survival data and two row rank order statistics arising in its consideration. Cancer Chemother Rep 50(3): 163–170
    1. Page DL (1991) Prognosis and breast cancer. Recognition of lethal and favorable prognostic types. Am J Surg Pathol 15(4): 334–349
    1. Pierga JY, Mouret E, Dieras V, Laurence V, Beuzeboc P, Dorval T, Palangie T, Jouve M, Vincent-Salomon A, Scholl S, Extra JM, Asselain B, Pouillart P (2000) Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patient with operable breast cancer. Br J Cancer 83(11): 1480–1487
    1. Sauerbrei W, Hubner K, Schmoor C, Schumacher M (1997) Validation of existing and development of new prognostic classification schemes in node negative breast cancer. German Breast Cancer Study Group. Breast Cancer Res Treat 42(2): 149–163
    1. Simpson JF, Gray R, Dressler LG, Cobau CD, Falkson CI, Gilchrist KW, Pandya KJ, Page DL, Robert NJ (2000) Prognostic value of histologic grade and proliferative activity in axillary node-positive breast cancer: results from the Eastern Cooperative Oncology Group Companion Study, EST 4189. J Clin Oncol 18(10): 2059–2069
    1. Sobin LH, Wittekind CH (1997) UICC – TNM Classification of Malignant Tumours, 5th edn. New York: Wiley-Liss
    1. Sundquist M, Thorstenson S, Brudin L, Nordenskjold B (1999) Applying the Nottingham Prognostic Index to a Swedish breast cancer population. South East Swedish Breast Cancer Study Group. Breast Cancer Res Treat 53(1): 1–8
    1. Van Praagh I, Amat S, Delva R, Leduc B, Mouret-Reynier MA, Lortholary A, Sillet-Bach I, Fleury J, Bonnel C, Feillel V, Penault-Llorca F, Le Bouedec G, Chollet P (2001) Induction chemotherapy in operable breast cancer by NET regimen: multicentric phase II trial (Meeting abstract). Proc ASCO 20: 35b [abstract no. 1889]
    1. Van Praagh I, Charrier S, Leduc B, Curé H, Le Bouëdec G, Achard J.L, Ferrière J.P, Feillel V, De Latour Monique, Dauplat J, Chollet P (2002) Efficacy of a primary chemotherapy regimen combining vinorelbine, epirubicin and methotrexate (VEM) as neoadjuvant treatment in 89 patients with operable breast cancer. Oncologist 7(5): 418–423

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere